BRPI0815111A2 - Processo para a preparação ou purificação de olmesartan medoxomil, sais de olmesartan medoxomil e seus usos e composições farmacêuticas - Google Patents

Processo para a preparação ou purificação de olmesartan medoxomil, sais de olmesartan medoxomil e seus usos e composições farmacêuticas

Info

Publication number
BRPI0815111A2
BRPI0815111A2 BRPI0815111-3A2A BRPI0815111A BRPI0815111A2 BR PI0815111 A2 BRPI0815111 A2 BR PI0815111A2 BR PI0815111 A BRPI0815111 A BR PI0815111A BR PI0815111 A2 BRPI0815111 A2 BR PI0815111A2
Authority
BR
Brazil
Prior art keywords
olmesartan medoxomil
purification
pharmaceutical compositions
salts
preparing
Prior art date
Application number
BRPI0815111-3A2A
Other languages
English (en)
Inventor
Samo Pirc
Lovro Selic
Original Assignee
Lek Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07114000A external-priority patent/EP2022790A1/en
Priority claimed from EP07114004A external-priority patent/EP2036904A1/en
Application filed by Lek Pharmaceuticals filed Critical Lek Pharmaceuticals
Publication of BRPI0815111A2 publication Critical patent/BRPI0815111A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0815111-3A2A 2007-08-08 2008-08-07 Processo para a preparação ou purificação de olmesartan medoxomil, sais de olmesartan medoxomil e seus usos e composições farmacêuticas BRPI0815111A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07114000A EP2022790A1 (en) 2007-08-08 2007-08-08 A process for the preparation or purification of olmesartan medoxomil
EP07114004A EP2036904A1 (en) 2007-08-08 2007-08-08 A process for the preparation of olmesartan medoxomil
PCT/EP2008/060396 WO2009019303A2 (en) 2007-08-08 2008-08-07 A process for the preparation or purification of olmesartan medoxomil

Publications (1)

Publication Number Publication Date
BRPI0815111A2 true BRPI0815111A2 (pt) 2015-01-27

Family

ID=39789494

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0815134-2A2A BRPI0815134A2 (pt) 2007-08-08 2008-08-07 Processo para a preparação de olmesartana medoxomila
BRPI0815111-3A2A BRPI0815111A2 (pt) 2007-08-08 2008-08-07 Processo para a preparação ou purificação de olmesartan medoxomil, sais de olmesartan medoxomil e seus usos e composições farmacêuticas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0815134-2A2A BRPI0815134A2 (pt) 2007-08-08 2008-08-07 Processo para a preparação de olmesartana medoxomila

Country Status (9)

Country Link
US (2) US8592474B2 (pt)
EP (2) EP2173741B1 (pt)
JP (2) JP5685082B2 (pt)
CN (2) CN101778843A (pt)
AT (1) ATE528305T1 (pt)
BR (2) BRPI0815134A2 (pt)
CA (2) CA2707334C (pt)
SI (1) SI2176253T1 (pt)
WO (2) WO2009019303A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2707334C (en) * 2007-08-08 2015-11-24 Lek Pharmaceuticals D.D. A process for the preparation or purification of olmesartan medoxomil
ES2540062T3 (es) 2008-06-09 2015-07-08 Daiichi Sankyo Company, Limited Procedimiento de producción de un compuesto de 1-bifenilmetilimidazol
TWI539948B (zh) 2009-04-28 2016-07-01 第一三共股份有限公司 奧美沙坦酯之製造方法
CA2760031C (en) 2009-04-28 2015-03-10 Daiichi Sankyo Company, Limited Acetone solvate crystals of trityl olmesartan medoxomil
WO2011007368A2 (en) * 2009-07-14 2011-01-20 Cadila Healthcare Limited An improved process for preparation of olmesartan
WO2011013096A1 (en) * 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Polymorphic form of olmesartan medoxomil
WO2011021224A2 (en) * 2009-08-19 2011-02-24 Msn Laboratories Limited Process for (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl4-(1-hydroxy-1-methylethyl)-2-propyl-1-[4-[2-tetrazol-5-yl)phenyl]phenyl]methylimidazole-5-carboxylate
CZ2010785A3 (cs) * 2010-10-29 2012-05-16 Zentiva, K.S. Zpusob výroby olmesartanu medoxomilu
KR101275092B1 (ko) * 2011-05-19 2013-06-17 한미정밀화학주식회사 아질사르탄의 개선된 제조방법
CN102351849B (zh) * 2011-10-26 2013-10-02 齐鲁天和惠世制药有限公司 一种奥美沙坦酯的制备方法
CN103304550B (zh) * 2012-03-16 2016-01-27 湖南欧亚生物有限公司 一种奥美沙坦酯的制备方法
CN103319461A (zh) * 2013-07-02 2013-09-25 临海天宇药业有限公司 奥美沙坦酯中间体的制备方法以及奥美沙坦酯的合成方法
CN103435602A (zh) * 2013-07-31 2013-12-11 山东省医学科学院药物研究所 一种奥美沙坦酯的制备方法
CN104262332A (zh) * 2014-09-16 2015-01-07 上海信谊百路达药业有限公司 一种奥美沙坦酯的制备方法
CN104447715B (zh) * 2014-11-28 2017-06-20 山东新华制药股份有限公司 奥美沙坦酯的制备方法
CN104817546B (zh) * 2015-05-20 2020-02-07 浙江华海药业股份有限公司 一种奥美沙坦酯母液回收的方法
CN107311990B (zh) * 2017-07-25 2021-09-03 浙江华海致诚药业有限公司 一种奥美沙坦酯的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616599A (en) * 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
DE69329982T2 (de) * 1992-06-02 2001-09-27 Sankyo Co 4-Carboxyimidazolderivate als Angiotensin-II-Antagonisten und ihre therapeutische Verwendung
JP2001226372A (ja) * 1999-12-06 2001-08-21 Sumika Fine Chemicals Co Ltd ロサルタンの結晶性または結晶化された酸付加塩およびロサルタンの精製方法
ITMI20032338A1 (it) * 2003-11-28 2005-05-29 Dinamite Dipharma S P A In Forma A Bbreviata Diph Composti feniltetrazolici.
CA2575177A1 (en) * 2004-09-02 2006-03-16 Teva Pharmaceutical Industries Ltd. Purification of olmesartan medoxomil
US7528258B2 (en) 2004-09-02 2009-05-05 Teva Pharmaceutical Industries Ltd Preparation of olmesartan medoxomil
GB2419592A (en) * 2004-10-26 2006-05-03 Cipla Ltd Process for the preparation of irbesartan hydrochloride
US20060281800A1 (en) 2005-04-12 2006-12-14 Glenmark Pharmaceuticals Limited Polymorphic form of olmesartan and process for its preparation
US7943779B2 (en) 2005-07-29 2011-05-17 Krka Process for the preparation of olmesartan medoxomil
EP1816131A1 (en) 2006-02-06 2007-08-08 KRKA, tovarna zdravil, d.d., Novo mesto Process for the preparation of olmesartan medoxomil
WO2007052301A2 (en) 2005-08-31 2007-05-10 Alembic Limited Process for the preparation of irbesartan
EP1801111B1 (en) * 2005-12-20 2014-07-16 LEK Pharmaceuticals d.d. Novel polymorph forms of olmesartan medoxomil
EP2016073B1 (en) 2006-04-07 2011-07-27 LEK Pharmaceuticals d.d. Process for the preparation of pure irbesartan
WO2007148344A2 (en) 2006-06-19 2007-12-27 Matrix Laboratories Limited Process for the preparation of olmesartan medoxomil
US8076492B2 (en) * 2006-10-09 2011-12-13 Cipla Limited Process for preparing trityl olmesartan medoxomil and olmesartan medoxomil
CA2707334C (en) * 2007-08-08 2015-11-24 Lek Pharmaceuticals D.D. A process for the preparation or purification of olmesartan medoxomil

Also Published As

Publication number Publication date
ATE528305T1 (de) 2011-10-15
WO2009019303A2 (en) 2009-02-12
CA2707334A1 (en) 2009-02-12
CN101778842B (zh) 2014-10-29
US20110263666A1 (en) 2011-10-27
JP2010535742A (ja) 2010-11-25
US8592474B2 (en) 2013-11-26
EP2173741B1 (en) 2013-10-02
SI2176253T1 (sl) 2012-02-29
CN101778842A (zh) 2010-07-14
EP2173741A1 (en) 2010-04-14
JP5685082B2 (ja) 2015-03-18
WO2009019303A3 (en) 2009-04-02
US20110224271A1 (en) 2011-09-15
BRPI0815134A2 (pt) 2015-02-03
CA2707334C (en) 2015-11-24
JP2010535743A (ja) 2010-11-25
CN101778843A (zh) 2010-07-14
EP2176253A2 (en) 2010-04-21
EP2176253B1 (en) 2011-10-12
CA2707365A1 (en) 2009-02-12
WO2009019304A1 (en) 2009-02-12

Similar Documents

Publication Publication Date Title
BRPI0815111A2 (pt) Processo para a preparação ou purificação de olmesartan medoxomil, sais de olmesartan medoxomil e seus usos e composições farmacêuticas
UA107929C2 (en) Antibodies against cxcr4 for the treatment of hiv infection
UY32062A (es) Inhibidores de beta-secretasa
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
IN2012DN02756A (pt)
ECSP14013217A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk.
BR112013026427A2 (pt) inibidores de replicação viral, seu processo de preparação e seus usos terapêuticos
MA32257B1 (fr) Hydroxymethyl pyrrolidines comme agonistes des recepteurs beta-3- adrenergiques.
UY32174A (es) Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones
GT201200158A (es) Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificación para su uso como principio activo farmacéutico
BR112013025987A2 (pt) derivados de pirimidina para o tratamento de infecções virais
NO20084850L (no) MGLUR5 modulatorer I
BR112012007234A2 (pt) combinação farmacêutica compreendendo inibidor de dpp-4 e metformina, bem como seu uso e seu processo de preparação
BR112012005225B8 (pt) Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente
TN2014000254A1 (en) Substituted triazolopyridines and their use as ttk inhibitors
BRPI0807487A8 (pt) Uso de antagonistas de il-23 para o tratamento de infecção
BR112014011219A8 (pt) Derivados de aminopirimidina, seus usos, e composição farmacêutica
BR112012023780A2 (pt) compostos complexos de ferro (iii) - b - cetoamida ou sais farmaceuticamente toleráveis desses, processo para a produção dos compostos complexos de ferro (iii), uso de compostos complexos de ferro (iii), fármaco contendo compostos complexos de ferro (iii) e composição contendo compostos complexos de ferro (iii)
BRPI0813427A2 (pt) Composto, uso do mesmo, método para tratar a infecção bacteriana em um animal de sangue quente, composição farmacêutica, e, processo para a preparação de um composto.
CL2013002027A1 (es) Formas cristalinas i y ii de (r)-1-etil-3-[6-fluoro-5-[2-(1-hidroxi-1-metil-etil)pirimidin-5-il]-7(tetrahidrofuran-2-il)-1h-benzimidazol-2-il]urea, inhibidor de girasa; composicion farmeceutica; y uso poara tratar o reducir una infeccion bacteriana.
BR112014012983A2 (pt) derivados de pirrol
BRPI0911678B8 (pt) maleato de orvepitant cristalino anidro, composição farmacêutica compreedendo o dito maleato e uso do mesmo para o tratamento ou profilaxia de doenças do sistema nervoso central
BR112012013325A2 (pt) Composição farmacêutica e uso
BRPI0923324A2 (pt) Composto, uso de um composto, método para inibição da dna girase e/ou topoisomerase iv bacteriana em um animal de sangue quente, e, processo para preparar um composto.
BR112014032964A2 (pt) composto, composição farmacêutica, uso do composto, e, método para preparar o composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL